Mast Therapeutics, Savara ink merger deal

Mast Therapeutics (NYSE:MSTX) and privately-held Savara Inc. said today that the 2 companies have landed a definitive merger agreement, combining their operations. The newly-formed Austin, Texas-based company is expected to be named Savara Inc., and trade on the NYSE market under a new ticker symbol.
The combined company will focus on advancing a pipeline of inhaled therapies, including AeroVanc to treat chronic methicillin-resistant Staphylococcus aureus pulmonary infection in cystic fibrosis, Molgradex to treat pulmonary alveolar proteinosis and AIR1001 to treat heart failure with preserved ejection fraction. All 3 treatments are in advanced clinical development.
Get the full story at our sister site, Drug Delivery Business News.
The post Mast Therapeutics, Savara ink merger deal appeared first on MassDevice.

Source: Mass Device - January 9, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Mergers & Acquisitions Pharmaceuticals Respiratory Wall Street Beat Mast Therapeutics Savara Inc. Source Type: news